# Ozempic's Hidden Powers: Heart Health, Addiction, and Global Access Breakthroughs

Welcome to Navigating OZMPIC, the show where we break down the latest news, science and real-world

impact of OZMPIC and other medications in its class. So listeners can make sense of a very

fast-moving story in health and lifestyle. Today we are focusing on a wave of new research

and policy developments that have landed in just the past few days.

These updates touch on everything, from how affordable OZMPIC could eventually become

around the world, to surprising new findings about the heart, addiction and what really happens

when you stop these medications. Let us start with cost and global access, because that is where

so many conversations about OZMPIC begin and end. According to a recent analysis reported by

stat news, scientists looking at the raw ingredient costs for semi-glutide, the active compound in

OZMPIC found that generic versions of OZMPIC and Wegovie could theoretically be mass-produced for

around $3 per person per month in low and middle income countries once patents expire and competition

arrives. The analysis estimated that the active ingredient could be manufactured for between $28

and $140 per year, which is dramatically lower than current retail prices in many high-income

markets. The key news is that patents for semi-glutide are starting to expire this month,

in countries including India, China, Canada, Brazil and Turkey, with a few more countries to follow

later this year. Stat News reports that this is expected to open the door for generic manufacturers,

especially in India to begin competing on price and to widen access for diabetes and obesity

treatment, far beyond wealthy healthcare systems. For listeners, this raises a big question.

If the medication can be made so cheaply, why is it still so expensive at the pharmacy counter?

That gap between possible manufacturing cost and actual price is likely to be a major policy

and political issue over the coming year, especially as more countries and insurers struggle

to cover demand. It also highlights a growing divide. On one hand, OZMPIC and similar drugs

are transforming care for people who can access them. On the other hand, most of the world still

cannot afford these treatments at scale, even for diabetes, let alone for obesity. The next

major story has to do with the heart, and it suggests that these drugs might do more than help

listeners lose weight or control blood sugar. Researchers at the University of Bristol and

University College London, in a study covered by Science Daily, have just reported that medications

like OZMPIC, WIGOVY and MANGARO may help protect the heart after a heart attack in a very

specific way. The study, published in the journal Nature Communications, looked at the complication

of heart attacks called no reflow. No reflow happens when doctors successfully reopen a blocked

major artery, but the tiny blood vessels deeper in the heart muscles stay narrowed. In up to half

of heart attack patients, this no reflow problem limits blood supply, raises the risk of further

damage, and increases the chance of heart failure or death within a year. The Bristol and

University College London team found that drugs in the OZMPIC family, known as Glucagan-like peptide

one receptor agonists, seemed to relax specialized cells called parasites that sit on those tiny

coronary vessels. In animal models, activating the Glucagan-like peptide one pathway opened up

these small vessels, improved blood flow, and reduced downstream heart damage. The lead researchers

suggest that medications like OZMPIC could be repurposed in the future as part of acute heart attack

care specifically to prevent no reflow, not just as chronic diabetes or weight loss drugs.

While this is still early stage and conducted in models rather than large human trials,

it adds to growing evidence that these medications have direct cardiovascular benefits

that go beyond simply reducing weight or blood sugar levels.

Another major thread

In the news is the impact of OZMPIC-like drugs on addiction and substance use.

Science magazine has just reported on a large study published in the British Medical Journal

that analyzed health records for more than 600,000 veterans in the United States.

In this study, people with diabetes who were prescribed a Glucagan-like peptide one drug,

such as semi-glutide, were compared to similar patients who used a different diabetes drug class

called sodium glucose-co-transporter-2 inhibitors. According to the researchers,

those on a Glucagan-like peptide one drug were 14% less likely to develop a new substance use

disorder involving alcohol, cannabis, cocaine, nicotine, or opioids.

Over three years, patients on these drugs had about 30% fewer drug-related emergency room visits.

25% fewer drug-related hospitalizations and roughly 40% fewer overdoses than those on the

comparison medications. Deaths related to substance use were about half as common

and suicidal thinking or attempts were lower as well. Experts quoted by Science described these

results as exciting, but also caution that this type of observational data cannot prove cause

an effect. It could be that patients on these drugs differ in important ways that the analysis

did not fully capture. Still, the findings align with earlier smaller trials suggesting that semi-glutide

might reduce alcohol intake in people with alcohol use disorder. Some clinicians are already

prescribing these medications off-label for addiction, but addiction researchers stress that

current evidence is not strong enough to replace established treatments. What this study does show

is that the Glucagan-like peptide-1 system, which ozemic targets, appears to influence reward pathways

in the brain in a fairly broad way, possibly dampening cravings not only for food, but for

several addictive substances. Larger randomized trials now underway will be critical in determining

whether ozemic or related drugs will become formally approved tools in addiction medicine.

So, we have heart-prote.